Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Roberto Ferrari(University of Ferrara), Alberico L. Catapano(University of Milan), Margus Viigimaa(Tallinn University of Technology), Jean Ferrières(Université Fédérale de Toulouse Midi-Pyrénées), Lâle Tokgözoğlu(Hacettepe University), Michel Farnier, Željko Reiner, Carlos Aguíar(Hospital de Santa Cruz), Moses Elisaf(University of Ioannina), Francesco Cosentino(Linköping University), Alberto Zambon(University of Padua), Nicolae Hâncu(Iuliu Hațieganu University of Medicine and Pharmacy), Alberto Mello e Silva(Hospital de Egas Moniz), Michal Vrablı́k(Charles University), Pasquale Perrone Filardi(Fondazione Toscana Gabriele Monasterio), P. Valensi(Hôpital Jean-Verdier), José Luis Zamorano(Hospital Universitario Ramón y Cajal), Eduardo Alegría(Policlínica Gipuzkoa), Meral Kayıkçıoğlu, Jesús Millán(Hospital General Universitario Gregorio Marañón), Riccardo C. Bonadonna(Azienda Ospedaliera Universitaria Integrata Verona)
Cited by 101
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k